BUSINESS● LOW2h ago · Sep 11, 2026, 12:32 PM
Novo Nordisk falls as Morgan Stanley cuts rating to Underweight on semaglutide concern
Seeking Alpha Tech · global
Novo Nordisk's stock has declined following Morgan Stanley's downgrade of its rating to Underweight, citing concerns related to semaglutide. This reports on a significant development affecting a pharmaceutical company's market performance.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS32m agoBlackRock MuniYield Quality Fund III declares $0.0555 dividendSeeking Alpha TechBUSINESS32m agoLeopold Aschenbrenner's Situational Awareness is active in options market, sources sayCNBC